Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Helocyte Inc.
DescriptionPeptide vaccine with human cytomegalovirus (CMV) phosphoprotein 65 (pp65; UL183) antigen combined with a toll-like receptor 9 (TLR9) agonist
Molecular Target Toll-like receptor 9 (TLR9) ; Human cytomegalovirus (CMV) phosphoprotein 65 (pp65) (UL83)
Mechanism of ActionVaccine; Toll-like receptor 9 (TLR9) agonist
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant and solid organ transplant recipients
Regulatory Designation
PartnerCity of Hope

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today